3 High-Yield Dividend Stocks Paying 5% or More That Are Worth Buying Now

The article highlights three high-yield dividend stocks with strong track records: Altria Group (MO) with a 5.91% yield and 57 years of consecutive dividend increases, Realty Income (O) offering 5.12% monthly dividends with 32 years of growth since going public, and Pfizer (PFE) yielding 7.12% despite post-COVID challenges. Each stock is positioned as a reliable income generator with potential for steady long-term returns.

07/12/2026, 3:25 AM • The Motley Fool

NCLA to Fifth Circuit: Revive Suit Against Gov’t-Led Censorship of Covid Vaccine-Injured Americans

The New Civil Liberties Alliance filed an appeal with the Fifth Circuit Court of Appeals challenging a district court's dismissal of a lawsuit alleging the Biden Administration orchestrated a censorship campaign targeting vaccine-injured individuals on social media. The case involves clients who suffered serious injuries or losses following COVID-19 vaccination and were censored when sharing their experiences online. NCLA argues the district court misapplied jurisdiction standards and Supreme Court precedent in dismissing the civil rights conspiracy claim.

07/08/2026, 6:38 PM • GlobeNewswire

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.

07/08/2026, 7:28 AM • The Motley Fool

2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now

Pfizer and Bristol Myers Squibb are presented as attractively valued dividend stocks despite recent challenges. Both pharmaceutical companies face patent cliffs but have strong pipelines with promising candidates in oncology, weight loss, and anticoagulants. With forward yields of 7.1% and 4.3% respectively, and trading at discounted valuations (8.2x and 9x forward earnings), they are recommended as potential buys for dividend investors with $1,000 to deploy.

07/07/2026, 6:30 PM • The Motley Fool

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

The transthyretin amyloidosis treatment market is projected to grow from USD 8.95 billion in 2025 to USD 35.10 billion by 2035 at a 14.64% CAGR. Growth is driven by increased ATTR-CM diagnosis rates, FDA approvals of gene-silencing therapies like vutrisiran and acoramidis, improved diagnostic imaging, and expanding pipeline therapies. North America dominates with 46% market share, while Asia Pacific is the fastest-growing region.

07/07/2026, 6:42 AM • GlobeNewswire

Meet the 4 S&P 500 Dividend Stocks That Yield at Least 6%. Here's My Strongest Buy of the Bunch in July.

The article examines four S&P 500 stocks with dividend yields exceeding 6%: Verizon, General Mills, Pfizer, and Kraft Heinz. Using metrics like yield, payout ratio, dividend growth history, and long-term returns, Verizon emerges as the strongest buy, offering sustainable dividend growth with positive 10-year returns and analyst support for 22% upside potential.

07/06/2026, 8:37 AM • The Motley Fool

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna and Recursion Pharmaceuticals represent two distinct approaches to biotech innovation: Moderna leverages proven mRNA technology with diversifying pipeline into oncology and rare diseases, while Recursion uses AI-driven drug discovery. Despite both operating at losses, Moderna is favored for 2026 due to its established revenue base and proven formula, whereas Recursion remains in earlier development stages with revenue expected to decline due to lower milestone payments.

07/03/2026, 11:14 AM • The Motley Fool

Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right.

Alnylam Pharmaceuticals has gained strong analyst support with 21 of 29 analysts rating it as buy or strong buy, with an average price target of $436 (45% upside). The company is transitioning from a clinical biotech to a profitable commercial powerhouse, with Q1 product revenue surging 121% year-over-year to $1.04 billion, driven by its ATTR franchise. The company's pipeline is expanding into mainstream markets like cardiomyopathy and hypertension, supported by a unique RNAi delivery platform that creates a competitive moat. However, the stock trades at a high valuation of 75x trailing earnings, with risks from competitive pricing pressure.

07/02/2026, 6:33 AM • The Motley Fool

Big Pharma Has a Case of Merger Mania

The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. While some firms like Eli Lilly are well-positioned, others like Merck and Pfizer face near-term patent expirations that could impact revenue significantly.

06/30/2026, 12:26 AM • The Motley Fool

AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?

AbbVie hit a new 52-week high and is up 40% over the past 12 months, though year-to-date gains are modest at 11%. Despite the elevated stock price, the company trades at less than 18x forward earnings—below the S&P 500 average of 21—making it reasonably valued. The pharmaceutical giant's recent $10.9 billion acquisition of Apogee Therapeutics and strong financial performance support its position as an attractive long-term dividend stock.

06/29/2026, 11:21 AM • The Motley Fool

A CFO Departure. A Clinical Miss. A $43 Billion Question Mark. Should You Throw in the Towel on Pfizer Stock?

Pfizer faces mounting challenges including a failed phase 3 clinical trial for cancer drug sigvotatug vedotin and the departure of CFO Dave Denton. Despite these setbacks and the $43 billion Seagen acquisition, the article argues the stock remains attractive due to strong pipeline candidates like MET-097i in weight loss, successful products like Padcev and Abrysvo, and a solid 7.3% dividend yield.

06/28/2026, 4:30 AM • The Motley Fool

Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now

Pfizer offers a compelling 6.9% dividend yield, significantly higher than the S&P 500's 1% yield, making it attractive for income investors despite being deeply out of favor on Wall Street. The stock has fallen 60% from its 2021 peak due to disappointing COVID vaccine sales and struggles in drug development, particularly missing out on the lucrative GLP-1 weight-loss drug category. However, the author argues that Pfizer's challenges are typical industry dynamics and the company's strong history suggests it will recover, making it a potential opportunity for long-term investors willing to tolerate near-term uncertainty.

06/27/2026, 3:15 PM • The Motley Fool

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?

RBC analyst Trung Huynh declared Eli Lilly the 'clear winner' at the American Diabetes Association conference, citing positive trial data for retatrutide and Foundayo. However, Novo Nordisk's chief science officer Martin Holst Lange argues the competition is far from over, noting that tolerability and effectiveness against comorbidities will play important roles. Eli Lilly reported 56% revenue growth last quarter, while Novo Nordisk experienced negative adjusted sales growth, creating a significant valuation gap between the two companies.

06/25/2026, 11:18 AM • The Motley Fool

Oblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development

Oblenio Bio announced the closing of a $62 million Series B financing round led by Pfizer Ventures, with participation from Deep Track Capital, GV, and Aditum Bio. The funds will support clinical development of LBL-051, a tri-specific T-cell engager designed to achieve immune system reset for autoimmune diseases. Recent preclinical data presented at EULAR 2026 demonstrated the program's ability to safely deplete B-cells and plasma cells without causing cytokine release syndrome, with the company planning to initiate first-in-human trials this year.

06/25/2026, 6:00 AM • GlobeNewswire

2 High-Yield Dividend Stocks to Buy and Hold for a Decade

The article recommends Pfizer and Medtronic as attractive dividend stocks for long-term investors seeking portfolio stability amid economic uncertainties. Despite recent challenges, both healthcare leaders offer compelling dividend yields (6.8% and 3.6% respectively) and have strong pipelines and growth opportunities that could drive returns over the next decade.

06/23/2026, 4:30 PM • The Motley Fool